Abstract Number: 2678 • 2017 ACR/ARHP Annual Meeting
Comparison of Scleroderma Associated Isolated Pulmonary Arterial Hypertension and Pulmonary Hypertension with Concomitant Interstitial Lung Disease
Background/Purpose: Relatively little data exist in the literature to characterize the differences between patients with scleroderma-associated isolated pulmonary arterial hypertension (SSc-PAH, WHO Group 1) and…Abstract Number: 2679 • 2017 ACR/ARHP Annual Meeting
Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Survival in scleroderma associated pulmonary arterial hypertension (SSc-PAH) is known to be significantly worse compared to that in idiopathic pulmonary arterial hypertension (iPAH). However,…Abstract Number: 1886 • 2016 ACR/ARHP Annual Meeting
Right Ventricular Load-Adaptability and Response to Therapy in Scleroderma Versus Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Recent studies have suggested that right ventricular (RV) adaptation in patients with scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is worse than in patients with idiopathic…Abstract Number: 1874 • 2015 ACR/ARHP Annual Meeting
Impact of Socioeconomic Status on Survival in Connective Tissue Disease Associated and Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Poorer health outcomes for persons with chronic diseases have been reported in association with lower socioeconomic status (SES). No such evaluation exists for patients…Abstract Number: 1717 • 2014 ACR/ARHP Annual Meeting
Endothelial to Mesenchymal Transition Contributes to the Development of Pulmonary Vasculopathy in Systemic Sclerosis PAH
Background/Purpose Vascular complications in Scleroderma (SSc) patients are associated with high mortality, particularly in patients who develop pulmonary arterial hypertension (SSc-PAH). Vascular complications, thought to…Abstract Number: 1706 • 2014 ACR/ARHP Annual Meeting
Prevention of SU5416-Induced Pulmonary Hypertension in a TGFβ Dependent Genetic Mouse Model of Scleroderma Using the Endothelin Receptor Antagonist Macitentan
Background/Purpose: Pulmonary arterial hypertension (PAH) is an important complication of systemic sclerosis (SSc) that occurs in around 10% of cases. We have previously shown that…Abstract Number: 731 • 2014 ACR/ARHP Annual Meeting
Performance of the Old ACR and the New ACR-EULAR Systemic Sclerosis Classification Criteria in Patients with Limited Cutaneous Disease: Effect on the Ascertainment of Severe Pulmonary Arterial Hypertension
Background/Purpose To analyze the performance of the old ACR1980 and the new ACR-EULAR2013 classification criteria for systemic sclerosis (SSc) in patients with limited disease in…Abstract Number: 2589 • 2013 ACR/ARHP Annual Meeting
Scleroderma Patients With Pulmonary Hypertension and Increased Pulmonary Capillary Wedge Pressure In The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
Background/Purpose: Systemic sclerosis (SSc) commonly leads to pulmonary hypertension (PH), which may be associated with left heart disease and an elevated pulmonary capillary wedge pressure…Abstract Number: 1812 • 2013 ACR/ARHP Annual Meeting
Adverse Events In Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared To Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Whether the risk of treatment-related adverse events (AEs) in patients with pulmonary arterial hypertension (PAH) differs based on diagnosis, either connective tissue disease (CTD-PAH)…Abstract Number: 1815 • 2013 ACR/ARHP Annual Meeting
Asymmetric Dimethylarginine Levels In The Early Detection Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc), and alterations in nitric oxide (NO) metabolism and endothelial cell…Abstract Number: 722 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis Associated Pulmonary Hypertension – Is Pulmonary Veno-Occlusive Disease As Common As They Say?
Background/Purpose: Recent reviews have suggested a high prevalence of pulmonary veno-occlusive disease (PVOD) amongst patients with systemic sclerosis (SSc) associated pulmonary hypertension (PH). Interlobular septal…Abstract Number: 1461 • 2012 ACR/ARHP Annual Meeting
Clinical Outcomes of Scleroderma Patients At High Risk for Pulmonary Hypertension. Analysis of the Pulmonary Hyparternsion Assessment and Recognition of Outcomes in Scleroderma Registry
Background/Purpose: Pulmonary hypertension (PH) is the most frequent cause of death in Systemic Sclerosis (SSc). It is critical to identify patients early to begin…Abstract Number: 1471 • 2012 ACR/ARHP Annual Meeting
Differential Expression of Hepatocyte Growth Factor (HGF) in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with systemic sclerosis (SSc). Non-invasive biomarkers are needed to identify…Abstract Number: 850 • 2012 ACR/ARHP Annual Meeting
Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). However, only a subset of SSc…Abstract Number: 851 • 2012 ACR/ARHP Annual Meeting
An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality and late-stage morbidity in systemic sclerosis (SSc). Current PAH screening recommendations are consensus-based and…
ACR Meeting Abstracts